|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 SEK | +3.60% |
|
+8.27% | -63.95% |
Scandion Oncology A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was DKK 39.2 million compared to DKK 76.7 million a year ago. Basic loss per share from continuing operations was DKK 0.96 compared to DKK 1.88 a year ago.
Diluted loss per share from continuing operations was DKK 0.96 compared to DKK 1.88 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -63.95% | 5.22M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -12.15% | 22.34B | |
| -2.56% | 21.93B | |
| -5.99% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
SCANDION ONCOLOGY A/S 